Mesoblast Limited reported $7.7M of revenue over the trailing twelve months, −24% on the year before. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $7.7M (to Q4 2023). Net income: −$82M, trailing twelve months to Q4 2023. EPS: −$0.11, trailing twelve months to Q4 2023.

MESOMesoblast Limited

Healthcare

$14.28-16% 1Y

$14.28

$13.6252 weeks$20.96

MESO as reported

Mesoblast Limited reported $7.7M of revenue over the trailing twelve months, −24% on the year before. 6 reported series are charted on this page, each one as filed.

$7.7M

Revenue, trailing twelve months · to Q4 2023 · −24% against the twelve months before

Net income: −$82M
Net income · −10% year on year · trailing twelve months to Q4 2023
EPS: −$0.11
EPS · −21% year on year · trailing twelve months to Q4 2023

Details›

Every series Ryufin has for MESO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$7.7M	−24%	Q4 2023
Net income	−$82M	−10%	Q4 2023
EPS	−$0.11	−21%	Q4 2023
Net margin	−1064%	n/a	Q4 2023
ROE	−17%	n/a	Q4 2023
ROA	−12%	n/a	Q4 2023

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.